DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,036,067 Girard Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,036,067 Girard Et Al United States Patent (19) 11 Patent Number: 5,036,067 Girard et al. 45 Date of Patent: Jul. 30, 1991 (54) DBENZOHETEROCYCLIC HYDROXAMIC 2191194A 6/1987 United Kingdom . ACDS AND HYDROXY UREAS AS OTHER PUBLICATIONS INHIBITORS OF 5-LPOXYGENASE P. K. Kadaba, The Synthesis of Some Phenothiazinyl (75) Inventors: Yves Girard; Pierre Hamel; Daniel Ketones and Their Derivatives, J. Het, Chen. 3, 345 Delorme, all of Quebec, Canada (1966). (73) Assignee: Merck & Co., Inc., Rahway, N.J. C. M. Suter, et al., The Directive Influences of Oxygen (21) Appl. No.: 493,527 and Sulfur, J.A.C.S. 58,717 (1936). Primary Examiner-C. Warren Ivy 22 Filed: Mar. 14, 1990 Assistant Examiner-Celia Chang (51) Int, Cl. ..................... A61K 31/54; A61K 31/55; Attorney, Agent, or Firm-Hesna J. Pfeiffer; Gabriel CO7D 279/18; CO7D 281/12 Lopez 52) U.S. C. ................................. 514/224.8; 514/21 i; 514/431; 514/434; 514/436; 540/551; 544/350; 57 ABSTRACT 544/38; 544/39; 549/10; 549/11; 549/12; 549/16; 549/17 Compounds having the formula I: (58) Field of Search .................... 540/551; 544/35, 38, 544/39; 549/10, 11, 12, 16, 17; 514/211, 224.8, R1 R3 431, 434, 436 (56) References Cited U.S. PATENT DOCUMENTS S OM 3,519,622 7/1970 Sutton ................................... 544/35 R2 3,639,612 2/1972 De Long............................... 544/35 (O) ck'l-N-y 4,536,507 8/1985 Rokach et al. ...................... 514/364 O 4,576,940 3/1986 Tahara et al. ....................... 514/212 4,666,907 5/1987 Fortin et al. ........................ 514/223 4,822,811 4/1989 Summers ............................. 514/411 are inhibitors of the 5-lipoxygenase enzyme. These 4,839,354 6/1989 Sunshine et al. 514/226.5 compounds are useful as anti-asthmatic, anti-allergic, 4,845,083 7/1989 Fortin et al. .......................... 54/80 anti-inflammatory, and cytoprotective agents. They are 4,873,259 10/1989 Summers et al. ................... 514/443 also useful in treating diarrhea, hypertension, angina, 4,889,874 12/1989 Haslanger et al................... 514/575 platelet aggregation, cerebral spasm, premature labor, FOREIGN PATENT DOCUMENTS spontaneous abortion, dysmenorrhea, and migraine. 0279263 2/1988 European Pat. Off. 87/04152 12/1986 United Kingdom . 9 Claims, No Drawings 5,036,067 1. DIBENZOHETERoCYCLIC HYDROXAMIC R1 ACDS AND HYDROXY UREAS AS INHIBITORS X OF 5-LPOXYGENASE BACKGROUND OF THE INVENTION OM The leukotrienes and their biological activities, espe 2 i cially their role in various disease states, have been R (O) extensively studied. Their properties are described in O O the book Leukotrienes and Lipoxygenase, Ed., J. Rokach, Elsevier, N.Y., 1989. Wherein: Inhibitors of the 5-lipoxygenase enzyme will prevent R1, R2 and R3 are independently: the biosynthesis of the various leukotrienes, and hence a) hydrogen, have a beneficial effect in those disease states in which 15 b) lower alkyl, the leukotrienes contribute to the disease. c) lower cycloalkyl, Various derivatives of hydroxylamine have been d) lower alkoxy, described as inhibitors of the 5-lipoxygenase enzyme. e) lower alkanoyloxy; Representative compounds are to be found in the fol f) -CF3 lowing patent documents: EP 196,184, EP279,263, WP 20 g) -CN, 87/04152, U.K. 2, 191,194 and U.S. Pat. No. 4,822,811. h) -NO2, i) -OR4, SUMMARY OF THE INVENTION The present invention relates to compounds having activity as inhibitors of the 5-lipoxygenase enzyme, to 25 methods for their preparation, and to methods and phar m) halogen; maceutical formulations for using these compounds in R4 is: mammals (especially humans). a) hydrogen, Because of their activity as inhibitors of 5-lipoxyge b) R5; 30 R5 is: nase, the compounds of the present invention are useful a) C1-C4 alkyl; as anti-asthmatic, anti-allergic, and anti-inflammatory R6 is: agents and are useful in treating allergic rhinitis and a) hydrogen, chronic bronchitis and for amelioration of skin diseases b) C1 to C4 alkyl, like psoriasis and atopic eczema. These compounds are 35 c) -COR4, also useful to inhibit the pathologic actions of leuko d) -S(O)2R, trienes on the cardiovascular and vascular systems for e) -C1-C4; alkylene-Ar example, actions such as result in angina or endotoxin R7 is: shock. The compounds of the present invention are a) hydrogen, useful in the treatment of inflammatory and allergic b) lower alkyl, diseases of the eye, including allergic conjunctivitis. c) Ar-lower alkyl, The compounds are also useful as cytoprotective agents Ar is: and for the treatment of migraine headache. a) R1 substituted phenyl, Thus, the compounds of the present invention may b) R1 substituted furyl, also be used to treat or prevent mammalian (especially, 45 c) R1 substituted thienyl; human) disease states such as erosive gastritis; erosive X is: esophagitis; inflammatory bowel disease; ethanol a) X, induced hemorrhagic erosions; hepatic ischemia; nox b) -CH=CH-, ious agent-induced damage or necrosis of hepatic, pan c) -CH2-CH2-, creatic, renal, or myocardial tissue; liver parenchymal 50 d) -CH2X-, damage caused by hepatoxic agents such as CC14 and e) -XCH2-, D-galactosamine; ischemic renal failure; disease f) NR7; induced hepatic damage; bile salt induced pancreatic or X1 is: gastric damage; trauma-or stress-induced cell damage; a) O, and glycerol-induced renal failure. 55 b) S, The compounds of this invention are inhibitors of the c) S(O), biosynthesis of 5-lipoxygenase metabolites of arachi d) S(O)2, donic acid, such as 5-HPETE, 5-HETE and the leuko e) NR6; trienes. Leukotrienes B4, C4, D4 and E4 are known to Y is: contribute to various disease conditions such as asthma, a) R4, psoriasis, pain, ulcers and systemic anaphylaxis. Thus b) -N(R')2; inhibition of the synthesis of such compounds will alle M is: viate these and other leukotriene-related disease states. a) hydrogen, b) -COAr, DETAILED DESCRIPTION OF THE 65 c) -CO-alkyl; INVENTION m is 1 to 5; The compounds of the present invention are repre n is 0 to 2; sented by formula I: and pharmaceutically acceptable salts thereof. 5,036,067 3 4. Alkyl, alkenyl, and alkynyl are intended to include refers to salts prepared from pharmaceutically accept linear and branched structures and combinations able non-toxic bases including inorganic bases and or thereof. ganic bases. Salts derived from inorganic bases include As used herein, the term "alkyl' includes "lower aluminum, ammonium, calcium, copper, ferric, ferrous, alkyl" and extends to cover carbon fragments having up lithium, magnesium, manganic salts, manganous, potas to 20 carbon atoms. Examples of alkyl groups include sium, sodium, zinc and the like. Particularly preferred octyl, nonyl, undecyl, dodecyl, tridecyl, tetradecyl, are the ammonium, calcium, magnesium, potassium and pentadecyl, eicosyl, 3,7-diethyl-2,2-dimethyl-4-propyl sodium salts. Salts derived from pharmaceutically ac nonyl, and the like. ceptable organic non-toxic bases include salts of pri As used herein, the term "lower alky' includes those O mary, secondary, and tertiary amines, substituted alkyl groups of from 1 to 7 carbon atoms. Examples of amines including naturally occurring substituted lower alkyl groups include methyl, ethyl, propyl, iso amines, cyclic amines and basic ion exchange resins, propyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, such as arginine, betaine, caffeine, choline, N,N-diben and the like. zylethylenediamine, diethylamine, 2-diethylaminoe The term "cycloalkyl' refers to a hydrocarbon con 15 thanol, 2-dimethylaminoethanol, ethanolamine, ethyl taining one or more rings having from 3 to 12 carbon enediamine, N-ethylmorpholine, N-ethylpiperidine, atoms, with the hydrocarbon having up to a total of 20 glucamine, glucosamine, histidine, hydrabamine, iso carbon atoms. Examples of cycloalkyl groups are cyclo propylamine, lysine, methylglucanine, morpholine, propyl, cyclopentyl, cycloheptyl, aldamantyl, cy piperazine, piperidine, polyamine resins, procaine, pu clododecylmethyl, 2-ethyl-1-bicyclo[4.4.0)decyl and 20 rines, theobromine, triethylamine, trimethylamine, tri the like. propylamine, tromethamine and the like. "Cycloalkenyl' groups include those alkenyl groups When the compound of the present invention is basic, of 3 to 20 carbon atoms, which include a ring of 3 to 12 salts may be prepared from pharmaceutically accept carbon atoms, and in which the alkenyl double bond able non-toxic acids, including inorganic and organic may be located anywhere in the alkenyl group. Exam 25 ples of cycloalkenyl groups are cyclopropen-1-yl, cy acids. Such acids include acetic, benzenesulfonic, ben clohexen-3-yl, 2-vinyladamant-1-yl, 5-methylenedodec zoic, camphorsulfonic, citric, ethanesulfonic, fumaric, i-yl, and the like. gluconic, glutamic, hydrobromic, hydrochloric, isethi As used herein, the term "lower alkoxy' includes onic, lactic, maleic, malic, mandelic, methanesulfonic, those alkoxy groups of from 1 to 7 carbon atoms of a 30 mucic, nitric, pamoic, pantothenic, phosphoric, suc straight, branched, or cyclic configuration. Examples of cinic, sulfuric, tartaric, p-toluenesulfonic acid and the lower alkoxy groups include methoxy, ethoxy, like. Particularly preferred are citric, hydrobromic, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, hydrochloric, maleic, phosphoric, sulfuric and tartaric and the like. acids. As used herein the term "lower alkylthio' includes 35 It will be understood that in the discussion of meth those alkylthio groups of from 1 to 7 carbon atoms of a ods of treatment which follows, references to the con straight, branched or cyclic configuration. Examples of pounds of Formula I are meant to also include the phar lower alkylthio groups include methylthio, propylthio, maceutically acceptable salts. isopropylthio, cycloheptylthio, etc. By way of illustra The ability of the compounds of Formula I to inhibit tion, the propylthio group signifies -SCH2CH2CH3; the 5-lipoxygenase enzyme makes them useful for inhib "lower alkylsulfinyl' and "lower alkylsulfonyl' refer to iting the symptoms induced by the leukotrienes in a the sulfoxides and sulfones of "lower alkylthio'.
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Chronic Pelvic Pain in Women (1 of 16)
    Chronic Pelvic Pain in Women (1 of 16) 1 Patient presents w/ symptoms suggestive of chronic pelvic pain (CPP) 2 3 COMMON EVALUATION Yes CAUSES OF CPP Do symptoms point to a • Treat according specific disease? to specifi c disease No 4 CHRONIC PELVIC PAIN SYNDROME CPPS EVALUATE & TREAT FOR SPECIFIC CONDITIONS: • Gastrointestinal Are • Gynecological symptoms organ Yes • Musculoskeletal specifi c? • Neurological • Psychological • Sexual No • Urological A MultidisciplinaryMIMS treatment CONSIDER GENERAL ANALGESIC TREATMENT OF CPP GENERAL ANALGESIC © TREATMENT OF CPP See next page B1 © MIMS 2019 Chronic Pelvic Pain in Women (2 of 16) GENERAL ANALGESIC TREATMENT OF CPP Is the pain neuropathic1 in nature? CHRONIC PELVIC PAIN CHRONIC PELVIC Yes No B Pharmacological therapy B Pharmacological therapy 1st-line trial agents: • Paracetamol • Amitriptyline or • NSAIDs • Gabapentin Alternative agents: • Nortriptyline • Pregabalin • Topical Capsaicin REFER BACK TO Is pain relief Yes PRIMARY CARE adequate? PHYSICIAN Is pain relief • CONTINUE Yes No adequate? TREATMENT • CONSIDER DOSE REDUCTION CONSIDER TRIAL No W/ NEUROPATHIC AGENTS • CONSIDER ADDING DIFFERENT 1STLINE AGENT • ROTATE AGENTS Is pain relief Yes adequate? Is pain relief Yes No adequate? MIMS No REFER TO PAIN SPECIALIST 1Please see Neuropathic© Pain disease management chart for further information. Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B2 © MIMS 2019 Chronic Pelvic Pain in Women (3 of 16) 1 CHRONIC
    [Show full text]
  • Formulations Comprising Nanoparticulate Meloxicam
    (19) TZZ¥ZZ¥__T (11) EP 3 090 731 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.11.2016 Bulletin 2016/45 A61K 9/14 (2006.01) A61K 31/5415 (2006.01) (21) Application number: 16161176.9 (22) Date of filing: 27.02.2004 (84) Designated Contracting States: • Ryde, Tuula AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Malvern, PA Pennsylvania 19355 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • Pruitt, John, D. Suwanee, GA Georgia 30024 (US) (30) Priority: 03.03.2003 US 450705 P • Kline, Laura Harleysville, PA Pennsylvania 19438 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Wichmann, Hendrik 08006465.2 / 1 938 803 Wuesthoff & Wuesthoff 04785761.0 / 1 617 816 Patentanwälte PartG mbB Schweigerstraße 2 (71) Applicant: DV Technology LLC 81541 München (DE) Wilmington, Delaware 19801 (US) Remarks: (72) Inventors: This application was filed on 18-03-2016 as a • Cooper, Eugene, R. divisional application to the application mentioned Berwyn, PA Pennsylvania 19312 (US) under INID code 62. (54) FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM (57) The present invention is directed to composi- than about 2 microns; wherein said effective average par- tions comprising meloxicam. The stable meloxicam com- ticle size is different than the particle size of the nano- positions comprise (a) nanoparticulate particles of mel- particulate particles of meloxicam (a); and (c) at least one oxicam having an effective average particle size of less surface stabilizer. The invention relates also to uses of than about 2000 nm, (b) particles of meloxicam having the composition.
    [Show full text]
  • European Patent Office
    (19) *EP003643305A1* (11) EP 3 643 305 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.04.2020 Bulletin 2020/18 A61K 31/196 (2006.01) A61K 31/403 (2006.01) A61K 31/405 (2006.01) A61K 31/616 (2006.01) (2006.01) (21) Application number: 18202657.5 A61P 35/00 (22) Date of filing: 25.10.2018 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • LAEMMERMANN, Ingo GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 1170 Wien (AT) PL PT RO RS SE SI SK SM TR • GRILLARI, Johannes Designated Extension States: 2102 Bisamberg (AT) BA ME • PILS, Vera Designated Validation States: 1160 Wien (AT) KH MA MD TN • GRUBER, Florian 1050 Wien (AT) (71) Applicants: • NARZT, Marie-Sophie • Universität für Bodenkultur Wien 1140 Wien (AT) 1180 Wien (AT) • Medizinische Universität Wien (74) Representative: Loidl, Manuela Bettina et al 1090 Wien (AT) REDL Life Science Patent Attorneys Donau-City-Straße 11 1220 Wien (AT) (54) COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS (57) The invention relates to a composition compris- ing senescent cells. The invention further relates to an ing one or more inhibitors capable of inhibiting at least in vitro method of identifying senescent cells in a subject two of cyclooxygenase-1 (COX-1), cyclooxygenase-2 and to a method of identifying candidate compounds for (COX-2) and lipoxygenase for use in selectively eliminat- the selective elimination of senescent cells. EP 3 643 305 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 3 643 305 A1 2 Description al.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Inflammatory Drug
    Abbreviations used: AR(s), adverse hepatotoxicity, 17 reaction(s); ADR(s), adverse drug manufacturers, 9 reaction(s); NSAID(s), non-steroid anti­ amorfazone, trade mark names and inflammatory drug(s) manufacturers, 9 Amuno, generic name and manufacturer, 12 anaemia absorption interactions, drug, 180-1 aplastic, 83 acemetacin, trade mark names and report rate, 33 manufacturers, 8 haemolytic, 84-5 acetyl salicylic acid, see Aspirin in rheumatoid patients, inappropriate action, drug, ~ pharmacoactivity therapy, 250 activation (of drugs), 243-5, 246, 247 anaphylaxis/anaphylactoid reactions, 17, pathway, 244 81 Actol, generic name and manufacturer, 13 Anaprox, generic name and manufacturer, Actosal, generic name and manufacturer, 13 9 angioedema, 6 acyl-coenzyme A formation, 221-2 angiotensin-converting enzyme, 195, 196 adjuvant induced arthritis, ~ inhibitors arthritis function, 195 Af1oxan, generic name and manufacturer, NSAID interactions with, 195-200 14 animal(s) age see also elderly experimentation, ethics of, 267 gastrointestinal susceptibility re­ inter species differences in lated to, 164, 286-8 propionate chiral inversion, use of anti-arthritics correlated 222-3, 223 with, 152 Ansaid, generic name and manufacturer, aged, the, ~ elderly 11 agranulocytosis antacids, 292 incidence, 7, 100-2 passim effect on drug absorption, 180, 181 in Sweden, 66, 67 NSAID interactions with, 185, 193 pyrazolone-induced, 7, 99-104 anthranilic acid, relative safety, 18 analytical epidemiological anti-arthritic drugs, ~ antirheumatic studies, 101-3 drugs
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Oral Non-Steroidal Anti-Inflammatory Drugs Versus Other Oral Analgesic Agents for Acute Soft Tissue Injury (Review)
    Cochrane Database of Systematic Reviews Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury (Review) Jones P, Dalziel SR, Lamdin R, Miles-Chan JL, Frampton C Jones P, Dalziel SR, Lamdin R, Miles-Chan JL, Frampton C. Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD007789. DOI: 10.1002/14651858.CD007789.pub2. www.cochranelibrary.com Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 7 OBJECTIVES ..................................... 8 METHODS ...................................... 8 RESULTS....................................... 12 Figure1. ..................................... 13 Figure2. ..................................... 17 Figure3. ..................................... 18 Figure4. ..................................... 23 Figure5. ..................................... 24 Figure6. ..................................... 25 ADDITIONALSUMMARYOFFINDINGS . 26 DISCUSSION ..................................... 34 AUTHORS’CONCLUSIONS . 36 ACKNOWLEDGEMENTS . 37 REFERENCES ....................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub
    US 2004O156872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0156872 A1 Bosch et al. (43) Pub. Date: Aug. 12, 2004 (54) NOVEL NMESULIDE COMPOSITIONS application No. 09/572,961, filed on May 18, 2000, now Pat. No. 6,316,029. (75) Inventors: H. William Bosch, Bryn Mawr, PA (US); Christian F. Wertz, Brookhaven, Publication Classification PA (US) (51) Int. Cl. ............................ A61K 9/14; A61K 9/00 Correspondence Address: FOLEY AND LARDNER (52) U.S. Cl. ............................................ 424/400; 424/489 SUTE 500 3000 KSTREET NW WASHINGTON, DC 20007 (US) (57) ABSTRACT (73) Assignee: Elan Pharma International Ltd. The present invention provides nanoparticulate nimeSulide (21) Appl. No.: 10/697,703 compositions. The compositions preferably comprise nime (22) Filed: Oct. 31, 2003 Sulide and at least one Surface Stabilizer adsorbed on or asSociated with the Surface of the nimeSulide particles. The Related U.S. Application Data nanoparticulate nimeSulide particles preferably have an effective average particle size of less than about 2000 nm. (63) Continuation-in-part of application No. 10/276,400, The invention also provides methods of making and using filed on Jan. 15, 2003, which is a continuation of nanoparticulate nimeSulide compositions. US 2004/O156872 A1 Aug. 12, 2004 NOVEL NMESULIDE COMPOSITIONS tion;' U.S. Pat. Nos. 5,399,363 and 5,494,683, both for “Surface Modified Anticancer Nanoparticles; U.S. Pat. No. RELATED APPLICATIONS 5,401,492 for “Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents,” 0001. This application is a continuation-in-part of U.S. U.S. Pat. No.
    [Show full text]
  • Pub. No.: US 2007/0231396 A1 Ray (43) Pub
    US 20070231396A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0231396 A1 Ray (43) Pub. Date: Oct. 4, 2007 (54) MEDICATION SPRAY FORMULATION Publication Classification (51) Int. Cl. A 6LX 36/899 (2006.01) A6IR 36/47 (2006.01) (76) Inventor: Charles D. Ray, Santa Barbara, CA A6II 3/56 (2006.01) (US) A6II 3/545 (2006.01) A 6LX 9/50 (2006.01) (52) U.S. Cl. ......................... 424/490; 424/731; 424/750; 514/200: 514/179 Correspondence Address: DICKE, BILLIG & CZAJA FIFTH STREET TOWERS (57) ABSTRACT 100 SOUTH FIFTH STREET, SUITE 2250 MINNEAPOLIS, MN 55402 (US) Formulations for delivery of a pharmaceutical agent include a thixotropic agent. The pharmaceutical agent may be slowly released from a hydrogel or microcapsule in the spray formulation. Various formulations of reasonable thixotropic (21) Appl. No.: 11/392.403 and hydrogel media are useful. Droplet size and thixotropy determine the distribution of the material along body sur faces and tissues such as the respiratory passages, and limit the displacement, running or dripping of the sprayed (22) Filed: Mar. 29, 2006 medium from its intended sites. US 2007/0231396 A1 Oct. 4, 2007 MEDCATION SPRAY FORMULATION would be welcomed by both manufacturers of health care products and consumers of Such products. FIELD OF THE INVENTION SUMMARY OF THE INVENTION 0001. The invention relates to thixotropic formulations for spray media delivery to body Surfaces and tissues such 0006 The present invention provides a thixotropic fluid as nasopharyngeal passages. The thixotropic effect allows media composition that is capable of being sprayed onto a for good fluidity during spraying but prevents running or patient's tissue (e.g., skin, wound, nasal cavity/mucous drippage loss of the medication from the body Surface so membrane), and generally consists of a primary carrier sprayed.
    [Show full text]
  • HHHHHHH USOO5081145A United States Patent (19) 11 Patent Number: 5,081,145 Guindon Et Al
    HHHHHHH USOO5081145A United States Patent (19) 11 Patent Number: 5,081,145 Guindon et al. 45 Date of Patent: Jan. 14, 1992 (54. INDOLE-2-ALKANOIC ACIDS 4,739,073 4/1988 Kathawala ...................... 548/414 X COMPOSITIONS OF AND ANT ALLERGIC USE THEREOF FOREIGN PATENT DOCUMENTS 50957 5/1982 European Pat. Off. (75. Inventors: Yvan Guindon; John W. Gillard, both 454858 6/1968 Switzerland. of Quebec; Christiane Yoakim, 455777 7/1968 Switzerland . Montreal; Thomas R. Jones, 948460 9/1960 United Kingdom . Kirkland; Rejean Fortin, Montreal-Nord, all of Canada OTHER PUBLICATIONS 73) Assignee: Merck Frosst Canada, Inc., Kirkland, Walton, et al., J. Med. Chen., 8, 204 (1965). Canada E. Walton, et al., J. Med. Chem., 11, 1252 (1968). 21 Appl. No.: 473,551 Primary Examiner-David B. Springer Attorney, Agent, or Firm-Gabriel Lopez; Joseph F. 22 Filed: Feb. 1, 1990 DiPrima 51. Int. Cl. .................. C07D 209/12; A61K 31/405 52 U.S. Cl. .................................... 514/49; 548/492; 57 ABSTRACT 548/494. Indole-2-alkanoic acids are disclosed. The compounds 58 Field of Search ......................... 548/494; 514/419 act as prostaglandin and thromboxane antagonists and 56 References Cited are useful in treating asthma, inflammation, diarrhea, hypertension, angina, platelet aggregation, cerebral U.S. PATENT DOCUMENTS spasm, premature labor, spontaneous abortion and dis 3,196,162 7/1965 Sarett et al. ......................... 260/39 menorrhea and as cytoprotective agents. 3,242,162 3/i966 Sarett et al. 260/21 3,242, 63 3/966 Sarett et al. ......................... 260/21 3,242,193 3/1966 Sarett et al. ......................... 260/319 6 Claims, No Drawings 5,081,145 1.
    [Show full text]